MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited Cash Conversion Cycle 2011-2026 | VNRX
Annual Cash Conversion Cycle VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.3 | 74.2 | 50.7 | 39.8 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 74.2 | 39.8 | 54.2 |
Quarterly Cash Conversion Cycle VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.3 | 42.3 | 55.3 | - | 46 | 34.5 | 100 | - | 63.8 | 66.5 | 58.2 | - | 19.5 | 92.8 | 33.9 | - | 63.4 | 55.4 | 38.2 | - | 1.13 K | 125 | 597 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.9 | 107 | 45.6 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 K | 19.5 | 135 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
275 | $ 2.83 | -4.39 % | $ 91.8 K |  USA |
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
111 | $ 116.37 | -1.49 % | $ 35.4 B | USA |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Charles River Laboratories International
CRL
|
65 | $ 173.71 | -2.76 % | $ 8.61 B | USA |
 |
Castle Biosciences
CSTL
|
45.9 | $ 27.4 | -2.11 % | $ 761 M | USA |
 |
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 15.93 | 1.14 % | $ 2.07 B | USA |
 |
Fulgent Genetics
FLGT
|
42.4 | $ 13.83 | -2.61 % | $ 418 M | USA |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
225 | $ 1.11 | -3.07 % | $ 1.41 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 205.94 | -2.06 % | $ 22.9 B | USA |
 |
Danaher Corporation
DHR
|
77.5 | $ 202.02 | -1.88 % | $ 144 B | USA |
 |
Exact Sciences Corporation
EXAS
|
42.5 | $ 103.3 | -0.05 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
208 | $ 8.64 | -1.48 % | $ 541 M | USA |
 |
DarioHealth Corp.
DRIO
|
207 | $ 10.5 | -2.33 % | $ 298 M |  Israel |
 |
DexCom
DXCM
|
134 | $ 73.05 | -1.0 % | $ 28.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B |  Niderland |
 |
Burning Rock Biotech Limited
BNR
|
149 | $ 24.2 | -3.82 % | $ 258 M | China |
 |
CareDx, Inc
CDNA
|
51.5 | $ 18.27 | -2.53 % | $ 974 M | USA |
 |
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | USA |
 |
ICON Public Limited Company
ICLR
|
62 | $ 105.46 | -2.6 % | $ 8.7 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
103 | $ 642.76 | 0.95 % | $ 51.7 B | USA |
 |
Illumina
ILMN
|
142 | $ 128.99 | -2.93 % | $ 20.5 B | USA |
 |
Guardant Health
GH
|
79.6 | $ 90.81 | -1.54 % | $ 11.4 B | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 171.78 | -1.43 % | $ 29.5 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
40.3 | $ 280.06 | -2.17 % | $ 23.3 B | USA |
 |
Co-Diagnostics
CODX
|
299 | - | - | $ 79.8 M | USA |
 |
Lantheus Holdings
LNTH
|
97.3 | $ 77.65 | 1.77 % | $ 5.24 B | USA |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 309.79 | -1.0 % | $ 27 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
49.3 | $ 4.93 | -1.6 % | $ 457 M | USA |
 |
NeoGenomics
NEO
|
82.4 | $ 9.13 | -3.89 % | $ 1.17 B | USA |
 |
Natera
NTRA
|
81.5 | $ 200.13 | 0.2 % | $ 19.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
185 | $ 1.51 | -7.1 % | $ 453 M | USA |
 |
Neogen Corporation
NEOG
|
150 | $ 10.97 | -1.61 % | $ 2.38 B | USA |
 |
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | USA |
 |
Precipio
PRPO
|
-3.19 | $ 24.5 | -0.73 % | $ 31.8 M | USA |